Do PCSK9 inhibitors do anything more than reduce LDL cholesterol?

Byrne and colleagues point out the lack of reliable evidence on cardiovascular risk with inclisiran, and the omens are not good.1 Inclisiran undoubtedly has a marked lowering effect on low density lipoprotein (LDL) cholesterol, which was first reported in 2017. But does a 30-50% reduction in LDL cholesterol translate to a 30-50% reduction in cardiovascular risk? Almost certainly not. The inclisiran results include an “exploratory cardiovascular endpoint” (a secondary …